Hasil Pencarian - Ofer Purim

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib

    Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib oleh Waleed Kian, Bilal Krayim, Hadel Alsana, Betsy Giles, Ofer Purim, Wafeek Alguayn, Farouq Alguayn, Nir Peled, Laila C. Roisman

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.

    A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. oleh Baruch Brenner, Michal Sarfaty, Ofer Purim, Yulia Kundel, Limor Amit, Amir Abramovich, Udi Sadeh Gonik, Efraim Idelevich, Noa Gordon, Gal Medalia, Aaron Sulkes

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.

    Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. oleh Yulia Kundel, Nicola J Nasser, Ofer Purim, Rinat Yerushalmi, Eyal Fenig, Raphael M Pfeffer, Salomon M Stemmer, Shulamith Rizel, Zvi Symon, Bella Kaufman, Aaron Sulkes, Baruch Brenner

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: